Sees FY25 adjusted EBITDA $40M-$44M. The company said, “Management projects 2025 revenue of approximately $517 million to $527 million and full year 2025 positive adjusted EBITDA of approximately $40 million to $44 million. Additionally, management expects modest cash flow generation for the full year 2025.”
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC:
- AtriCure reports preliminary Q4 revenue $124.3M, consensus $119.85M
- AtriCure ups FY24 revenue view to $465.3M from $459M-$462M, consensus $460.89M
- AtriCure Projects Strong Revenue Growth for 2024
- AtriCure assumed with an Overweight at JPMorgan
- AtriCure price target raised to $61 from $53 at Canaccord